Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd shows a strong growth outlook driven by its lead asset, Brukinsa, which has established a leading position in the BTK inhibitor market, with projected peak sales reaching approximately $7.1 billion by 2034. The company’s sonrotoclax, touted as the most advanced BCL2 inhibitor, exhibits improved efficacy and safety compared to existing treatments, bolstering expectations for significant additional revenue, estimated at around $3.4 billion. This positive trajectory is further supported by planned physician outreach and competitive contracting strategies, which are anticipated to drive over 40% year-over-year growth, positioning BeOne towards profitable operations and positive free cash flow by 2025.

Bears say

BeOne Medicines Ltd faces a negative outlook primarily due to the possibility of slower-than-expected commercial uptake of its products and potential failures in its pipeline initiatives, which includes the solid tumor initiative and sonrotoclax, that could severely impact financial viability. Moreover, key risks such as significant cash burn without resulting marketable drugs, perceived geopolitical risks associated with the company’s Chinese origin, and challenges in a crowded heme-oncology space could further weaken the company’s competitive positioning. Additionally, any adverse regulatory decisions, unexpected safety signals, or delays in product development and commercialization could negatively affect market potential and future earnings projections.

BeiGene Ltd (ONC) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 10 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $384.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $384.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.